Patents by Inventor Kazunori Hanada
Kazunori Hanada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 5922743Abstract: A pyridine derivative represented by the following formula: ##STR1## where R.sup.1 and R.sup.2 are as defined in the specification, or a salt thereof. These compounds directly or indirectly act on neuronal cells in vivo and are effective in the amelioration and curing of nerve disorders due to neuronal degeneration, such as, for example, traumatic symptoms and maladies, disorders induced by drugs such as alcohol and antineoplastic agents, inflammatory disorders, metabolic disorders observed in diabetes, and disorders due to idiopathic degeneration of peripheral nerves. These compounds are also effective for ameliorating and curing symptoms and maladies due to degeneration of central nerves, for example, Alzheimer's disease and cerebrovascular ischemia, Down's syndrome, Parkinson's disease, Huntington's chorea, diseases secondary to cerebral ischemia, cerebral infarction, intracerebral bleeding, head injuries, amnesia, and spinal neuropathy.Type: GrantFiled: August 7, 1997Date of Patent: July 13, 1999Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Hirofusa Shirai, Kenji Hanabusa, Yuki Takahashi, Fumio Mizobe, Kazunori Hanada
-
Patent number: 5807711Abstract: A novel parenchymal hepatocyte growth factor originating in a human or animal liver, having an estimated molecular weight according to nonreductive SDS-PAGE of about 63,000 to about 69,000, an estimated molecular weight according to reductive SDS-PAGE of about 32,000 to about 36,000 and an estimated molecular weight according to gel filtration of about 60 to about 70 Kd; and having an activity of effecting the growth of parenchymal hepatocyte has been obtained from the hemihepatectomized tissue. Furthermore, a gene coding for the above substance has been obtained from the mRNA of the above tissue and it has thus become possible to mass-produce the above substance.Type: GrantFiled: September 22, 1995Date of Patent: September 15, 1998Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Hiroshi Hara, Hiromitsu Yoshimura, Yumiko Matsuki, Saeko Shindo, Kazunori Hanada
-
Patent number: 5783417Abstract: A DNA fragment encoding a novel human-derived tumor cell growth inhibitor can be obtained from a cDNA library originating from human colon tumor cell, using as a DNA probe a DNA fragment encoding mouse human-derived tumor cell growth inhibitor. An expression plasmid bearing a promoter originating from Bacillus brevis, a signal peptide originating from Bacillus brevis and a DNA fragment encoding human-derived tumor cell growth inhibitor downstream of the signal peptide is constructed and Bacillus brevis is transformed by the expression plasmid. The resulting transformant is incubated to secret the novel inhibitor out of the cell so that the novel inhibitor can be produced efficiently.Type: GrantFiled: February 5, 1996Date of Patent: July 21, 1998Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Toshi Komurasaki, Kiyoshi Nakazawa, Hitoshi Toyoda, Masayoshi Takahashi, Daisuke Uchida, Kazunori Hanada, Shigezo Udaka
-
Patent number: 5523391Abstract: DNA fragments encoding a tumor cell growth inhibitors and having a nucleotide sequence shown by formula (1) below, which are produced by preparing cDNA library from mRNA of the established 3T3 cell-derived cell line, amplifying various DNA fragments considered to encode the tumor cell growth inhibitors by the PCR method, analyzing the nucleotide sequences of these DNA fragments and determining the nucleotide sequences of the DNA fragments encoding the inhibitors: ##STR1## wherein X represents TTC TTT CTA or TTC (SEQ ID NO:1 or SEQ ID NO:2).Type: GrantFiled: May 25, 1994Date of Patent: June 4, 1996Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Toshi Komurasaki, Hitoshi Toyoda, Makoto Yoshimoto, Kazunori Hanada
-
Patent number: 5384394Abstract: Novel tumor cell growth inhibitor is a protein which can be obtained from the culture supernatant of 3T3 cell-derived cell line and which has the following properties:(a) molecular weight 3,700.+-.370 daltons when measured by SDS polyacrylamide gel electrophoresis under reducing and non-reducing conditions;(b) column propertythe inhibitor is not substantially adsorbed onto an anionic exchange resin column at pH of about 7.4 but is substantially adsorbed onto a cationic exchange resin column at pH of about 5.0The inhibitor has an inhibitory activity on human promyelogenic leukemia cells and human uterocervical tumor-derived cells and is useful for the treatment of leaukemia or uterus tumor.Type: GrantFiled: February 10, 1994Date of Patent: January 24, 1995Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Toshi Komurasaki, Hitoshi Toyoda, Daisuke Uchida, Kazunori Hanada
-
Patent number: 5068354Abstract: An epoxysuccinic acid derivative represented by the formula ##STR1## wherein R.sup.1 is a hydrogen atom or an alkyl group containing 1 to 4 carbon atoms, and a pharmaceutically acceptable salt are useful as cathepsin B inhibitors.Type: GrantFiled: May 2, 1990Date of Patent: November 26, 1991Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Mitsuo Murata, Chihiro Yokoo, Kazunori Hanada
-
Patent number: 4902781Abstract: Tripeptide derivatives of the formula ##STR1## wherein R is a formyl group or a dimethoxymethyl group have antitumor and enzyme inhibition effects.Type: GrantFiled: November 21, 1988Date of Patent: February 20, 1990Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Kazutoshi Mizoue, Tadayasu Okazaki, Kazunori Hanada, Sadafumi Omura, Toshiro Amamoto
-
Patent number: 4507232Abstract: This invention is directed to novel peptide derivatives. Said peptide derivatives are useful as a substrate for the activity assay of enzymes of the group EC 3. 4. 22, for example, cathepsin L, cathepsin B and cathepsin H. Said peptide derivatives which contain L-methionine radical are prepared according to the methods conventional in peptide chemistry. As typical examples are mentioned D-leucyl-L-tyrosyl-L-methionine-.beta.-naphthylamide formate, .beta.-alanyl-L-tyrosyl-L-methionine-.beta.-naphthylamide formate and succinyl-L-tyrosyl-L-methionine-p-nitroanilide.Type: GrantFiled: December 16, 1983Date of Patent: March 26, 1985Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Masaharu Tamai, Takashi Adachi, Kiyoshi Oguma, Kazunori Hanada, Sadafumi Omura, Nobuhiko Katunuma
-
Patent number: 4474800Abstract: An epoxysuccinyl amino acid derivative of the formula ##STR1## wherein R.sup.1 is hydrogen, alkali metal, benzyl or cycloalkyl having 5 to 6 carbon atoms, R.sup.2 is alkyl having 3 to 4 carbon atoms, R.sup.3 is hydrogen, benzyloxycarbonyl, acetyl or benzoyl, and n is an integer of 2 to 7. The subject compounds exhibit inhibitory activity towards thiol protease, especially, calcium-activated neutral thiol protease which exists in excess in muscle tissues of mammals afflicted with muscular dystrophy.Type: GrantFiled: May 13, 1980Date of Patent: October 2, 1984Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Masaharu Tamai, Shigeo Morimoto, Takashi Adachi, Kiyoshi Oguma, Kazunori Hanada, Sadafumi Omura
-
Patent number: 4418075Abstract: An epoxysuccinyl amino acid derivative of the formula ##STR1## wherein R.sup.1 is hydrogen or alkali metal, R.sup.2 is isobutyl, R.sup.3 is hydrogen or benzyloxycarbonyl, and n is an integer of 5 to 7. The subject compounds exhibit inhibitory activity towards thiol protease, especially, calcium-activated neutral thiol protease which exists in excess in muscle tissues of mammals afflicted with muscular dystrophy.Type: GrantFiled: November 10, 1981Date of Patent: November 29, 1983Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Masaharu Tamai, Shigeo Morimoto, Takashi Adachi, Kiyoshi Oguma, Kazunori Hanada, Sadafumi Omura
-
Patent number: 4393228Abstract: The epoxysuccinic acid derivatives of this invention are prepared by esterification of an epoxysuccinic acid or a halide thereof, by partial hydrolysis of an epoxysuccinic acid diester, by amidation of an epoxysuccinic acid monoester, or by hydrolysis of an epoxysuccinic acid amide monoester. These epoxysuccinic acid derivatives have excellent thiol protease inhibitory activity and anti-inflammatory activity without the acceleration of vascular permeability.Type: GrantFiled: February 22, 1978Date of Patent: July 12, 1983Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Jiro Sawada, Kazunori Hanada, Masaharu Tamai, Shigeo Morimoto, Sadafumi Omura
-
Patent number: 4387238Abstract: The epoxysuccinamic acid compounds of the present invention are prepared by reaction of monoesters of epoxysuccinic acid or monoesters of epoxysuccinic acid chloride with amino compounds. These epoxysuccinamic acid compounds have excellent anti-inflammatory activity, thiol protease inhibitory activity, muscular dystrophy inhibitory activity and anti-hypertensive activity without acceleration of vascular permeability.Type: GrantFiled: May 14, 1981Date of Patent: June 7, 1983Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Masami Goi, Kazuya Kameo, Jiro Sawada, Kazunori Hanada, Masaharu Tamai, Kiyoshi Oguma
-
Patent number: 4382889Abstract: An epoxysuccinic acid derivative of the formula ##STR1## wherein R.sup.1 is hydrogen, alkali metal, alkyl having 1-2 carbon atoms, cycloalkyl having 5-6 carbon atoms or benzyl, R.sup.2 is alkyl having 3-4 carbon atoms or benzyl, R.sup.3 is hydrogen or methyl, and R.sup.4 is alkyl having 1-10 carbon atoms, phenyl, benzyl, phenethyl, cycloalkyl having 3-6 carbon atoms or a group of the formula ##STR2## wherein R.sup.5 is hydrogen, alkyl having 1-4 carbon atoms or said alkyl substituted with hydroxy, methylmercapto, phenyl, hydroxyphenyl, indolyl, an optionally protected carboxy, an optionally protected amino or an optionally protected guanidino, and R.sup.6 is hydroxy, alkalimetaloxy, alkoxy having 1-2 carbon atoms, benzyloxy, amino or dimethylamino, or R.sup.3 and R.sup.4 taken together with the nitrogen atom to which they are attached form a 5-6 membered heterocyclic ring, or said heterocyclic ring substituted with a protected carboxy.Type: GrantFiled: December 30, 1981Date of Patent: May 10, 1983Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Masahuru Tamai, Takashi Adachi, Shigeo Morimoto, Kiyoshi Oguma, Kazunori Hanada, Sadafumi Omura
-
Patent number: 4333879Abstract: An epoxysuccinic acid derivative of the formula ##STR1## wherein R.sup.1 is hydrogen, alkali metal, alkyl having 1-2 carbon atoms, cycloalkyl having 5-6 carbon atoms or benzyl, R.sup.2 is alkyl having 3-4 carbon atoms or benzyl, R.sup.3 is hydrogen or methyl, and R.sup.4 is alkyl having 1-10 carbon atoms, phenyl, benzyl, phenethyl or cycloalkyl having 3-6 carbon atoms or R.sup.3 and R.sup.4 taken together with the nitrogen atom to which they are attached form a 5-6 membered heterocyclic ring, or said heterocyclic ring substituted with a protected carboxy.Type: GrantFiled: January 3, 1980Date of Patent: June 8, 1982Assignee: Taisho Pharmaceutical Co., Ltd.Inventors: Masaharu Tamai, Takashi Adachi, Shigeo Morimoto, Kiyoshi Oguma, Kazunori Hanada, Sadafumi Omura